Which ALL Patients Will Develop Cytokine Release Syndrome After Therapy: Identifying Predictive Biomarkers

nurse talking to patient in hospital bed

Chimeric antigen receptor (CAR)-modified T cells with anti-CD19 specificity offer a highly effective, novel immune therapy for patients with relapsed/refractory acute lymphoblastic leukemia (ALL). But we need better information about Cytokine Release Syndrome (CRS)—the most common severe toxicity we see after they undergo this targeted immunotherapy. The authors developed statistical models using patient characteristics at the time of and immediately following CTL019 therapy, to predict which patients would go on to develop severe CRS. These models accurately predicted which patients developed severe CRS—information that improves our understanding of CRS biology and may guide future cytokine-directed therapy.

Read the article in Cancer Discovery.


David T. Teachey, Simon F. Lacey, Pamela A. Shaw, J. Joseph Melenhorst, Shannon L. Maude, Noelle Frey, Edward Pequignot, Vanessa E. Gonzalez, Fang Chen, Jeffrey Finklestein, David M. Barrett, Scott L. Weiss, Julie C. Fitzgerald, Robert A. Berg, Richard Aplenc, Colleen Callahan, Susan R. Rheingold, Zhaohui Zheng, Stefan Rose-John, Jason C. White, Farzana Nazimuddin, Gerald Wertheim, Bruce L. Levine, Carl H. June, David L. Porter and Stephan A. Grupp